Skip to content

Study · Observational study · n = 59 · 2022

3 results

Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.

Yoshiji S, Hasebe M, Iwasaki Y, Shibue K, Keidai Y, Seno Y, Iwasaki K, Honjo S, Fujikawa J, Hamasaki A

Diabetes therapy : research, treatment and education of diabetes and related disorders13 Mar 2022Cited by 3 (Europe PMC)

PMID35285007 (opens in a new tab)PMCIDPMC8991285 (opens in a new tab)DOI10.1007/s13300-022-01231-1 (opens in a new tab)PepBankPUB-35285007
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with diabetes continuing dulaglutide without additional medication, HbA1c decreased significantly from baseline.

    In plain wordsIn patients with diabetes, dulaglutide use was linked to lower HbA1c than at baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n = 59

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change 0-6 months
    −1.16%
    patients continuing dulaglutide for at least 6 months without initiating additional glucose-lowering medications, mean ± SE 0.17

    Source sentences

    Summary
    Mean ± SE HbA1c change 0-6 months was - 1.16 ± 0.17% (P < 0.001 vs. baseline).
    3 context sentences
    Summary · context
    We evaluated FCPR, PCPR, and ΔCPR levels in patients with type 2 diabetes who initiated dulaglutide treatment after a standardized meal tolerance test (MTT).
    Summary · context
    Then, we evaluated the association between each β-cell function marker and glycemic response (HbA1c change 0-6 months) to dulaglutide using generalized linear model and logistic regression analysis with adjustment for baseline HbA1c.
    Summary · context
    Of all patients, 59 continued dulaglutide for at least 6 months without initiating any additional glucose-lowering medications.

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther

    In dulaglutide-treated patients with diabetes, beta-cell function markers were significantly associated with HbA1c change after baseline HbA1c adjustment.

    In plain wordsIn dulaglutide users, beta-cell markers were linked to HbA1c changes after adjustment for starting HbA1c.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableC-peptide markers and HbA1c response
    Study

    n = 59

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The β-cell function markers were significantly associated with HbA1c change 0-6 months in the generalized linear model.
    3 context sentences
    Summary · context
    We evaluated FCPR, PCPR, and ΔCPR levels in patients with type 2 diabetes who initiated dulaglutide treatment after a standardized meal tolerance test (MTT).
    Summary · context
    Then, we evaluated the association between each β-cell function marker and glycemic response (HbA1c change 0-6 months) to dulaglutide using generalized linear model and logistic regression analysis with adjustment for baseline HbA1c.
    Summary · context
    Of all patients, 59 continued dulaglutide for at least 6 months without initiating any additional glucose-lowering medications.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther

    In dulaglutide-treated patients, fasting C-peptide predicted an HbA1c reduction of at least 1%, with an ROC area of 0.83.

    In plain wordsIn dulaglutide users, fasting C-peptide helped predict an HbA1c reduction of at least 1%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableFasting C-peptide prediction of HbA1c response
    Study

    n = 59

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    ROC area
    0.83 unitless
    fasting C-peptide
    Sensitivity
    0.81 unitless
    fasting C-peptide
    Specificity
    0.79 unitless
    fasting C-peptide

    Source sentences

    Summary
    FCPR was also a significant predictor for achieving a reduction in HbA1c of at least 1% (P = 0.044) with an area under the receiver operating characteristic curve of 0.83 (sensitivity = 0.81 and specificity = 0.79).
    3 context sentences
    Summary · context
    We evaluated FCPR, PCPR, and ΔCPR levels in patients with type 2 diabetes who initiated dulaglutide treatment after a standardized meal tolerance test (MTT).
    Summary · context
    Then, we evaluated the association between each β-cell function marker and glycemic response (HbA1c change 0-6 months) to dulaglutide using generalized linear model and logistic regression analysis with adjustment for baseline HbA1c.
    Summary · context
    Of all patients, 59 continued dulaglutide for at least 6 months without initiating any additional glucose-lowering medications.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.